Navigation Links
Takeda submits new drug application for alogliptin (syr-322) in the US
Date:1/4/2008

Deerfield, IL, January 3, 2008 --- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes. Discovered by Takeda San Diego, Inc., alogliptin was designed to selectively inhibit DPP-4 taken orally once daily.

DPP-4 inhibitors are a new class of oral agents for the treatment of type 2 diabetes, which slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). The incretins play a major role in regulating blood glucose levels and may have the potential to improve pancreatic beta-cell function.

The NDA submission was supported by six Phase 3 clinical trials involving over 2,000 patients conducted in 220 centers worldwide. The safety and efficacy of alogliptin was studied as a once-daily monotherapy adjunct to diet and exercise and as an add-on therapy to other antidiabetic medications including sulfonylureas, metformin, thiazolidinediones (TZDs), and insulin. In the studies, alogliptin was associated with statistically significant reductions in hemoglobin A1c, which reflects average blood glucose concentration over the previous two to three months. Alogliptin was generally well-tolerated and weight neutral. There was no increase in hypoglycemia compared to placebo.

The NDA submission for alogliptin is a significant milestone for Takeda, as it has the potential to position us as one of the global leaders in diabetes treatment, said Yasuchika Hasegawa, president of Takeda. Takedas continued growth, now and in the future, will be based on our ability to focus and have success in this therapeutic area. Our hope is that alogliptin will become an important t
'/>"/>

Contact: Carrie Rose
carrie.rose@ketchum.com
646-935-3938
Takeda Pharmaceuticals North America
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Chemizon Announces Research Collaboration Expansion With Takeda
2. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
3. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
4. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
5. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
6. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
7. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
8. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
9. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
10. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... nursing facilities (SNFs) in Ohio are making major changes ... a 92 percent increase in the state-imposed Medicaid bed ... bed per day, scheduled for December 15. The ... additional $17,520 to the state each month, or $210,240 ... ,, Nearly 96 percent of skilled nursing facilities responding ...
(Date:12/14/2009)... to Stemming Tide of Tens of Thousands of ... Dec. 14 Legislation approved by Congress ... be crucial in helping to reduce tens of ... year in the United States, the National ... The provision was included in the FY 2010 ...
(Date:12/14/2009)... The Hemophilia Federation of America (HFA) ... involving the Teamsters Local 929 and the American ... blood system depends on skilled workers to provide ... distilled into products such as clotting factor for ... ,, The Division of Blood Services at ...
(Date:12/14/2009)... When Kurth Krause, an aerospace engineer,for NASA, was ... the moon, he,was confident that technology and science ... there was one thing that science couldn,t solve.,His ... though dialysis machines,would keep her alive for awhile, ... wife is 69 and is starting dialysis next ...
(Date:12/14/2009)... be linked to scans performed in 2007 , , MONDAY, ... exposing patients to far more radiation than previously thought and ... a year, two new studies claim. , Based on the ... Archives of Internal Medicine , the study authors, joined by ... on clinicians to limit radiation exposure to patients. , "CT ...
Breaking Medicine News(10 mins):Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:HFA Voices Blood Safety Concerns 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4
... Technology , , SOMERVILLE, ... device company, today announced the launch of the PROCEED ... family of hernia products. PVP Device is the first ... and exclusive, absorbable deployment technology. It is indicated for ...
... , , SEATTLE, Dec. 16 ... Hutchinson Cancer Research Center,s "Get Screened" video contest - a creative ... screening. All entries are due by Jan. 15, 2009. , ... Hutchinson Center,s ongoing awareness campaign - "Your colon. Your life. ...
... 16 The ASCII Group, Inc. (ASCII), the nation,s ... has announced a partnership with Association Health Programs (AHP) ... the cost of health insurance. The program will ... a comprehensive health insurance program for individuals, families, groups, ...
... Programs and Next Year,s Services , , ... Chicago is facing a grave financial shortfall which will severely ... of donations increases this Christmas season according to its commanding ... , "The economic downturn has attacked us on ...
... Improve Ease of Use and Speed , , BOSTON, ... improved version of its producer website ( www.jhltc.com ) to make it easier for ... tools online. , , Enhancements to the site include: ... Faster speed of processing , ...
... deadly,bacteria in lungs , , TUESDAY, Dec. 16 (HealthDay News) ... in the lungs of cystic fibrosis patients are signaling ... The pigments may enable infectious Pseudomonas aeruginosa ... Massachusetts Institute of Technology (MIT) study. , The ...
Other Medicine News:Health News:ETHICON Launches the Latest Innovation in Hernia Repair Platform; PROCEED(TM) Ventral Patch (PVP(TM) Device) 2Health News:A Month Left to Enter the 'Get Screened' Video Contest for a Chance to Win Up to $2,500 2Health News:The ASCII Group Partners with Association Health Programs to Counter Rising Health Insurance Costs 2Health News:Salvation Army Services Threatened by Pace of Donations 2Health News:John Hancock LTC Enhances Producer Website 2Health News:John Hancock LTC Enhances Producer Website 3Health News:Scientists Spot Key to Cystic Fibrosis Infections 2
(Date:12/14/2009)... Dec. 14 In response to an ... 2009, in which the Agency recommended that healthcare ... (SS1) sterile processing system, hospitals throughout the U.S. ... alternatives to that product. According to the FDA, ... SS1 that may affect the safety or the ...
(Date:12/14/2009)... 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... Drug Application (NDA) for Staccato® loxapine (AZ-004) to the ... an inhalation product candidate being developed for the rapid ... disorder. The IND for Staccato loxapine ... "AZ-004 has delivered a predictable and consistent safety and ...
(Date:12/14/2009)... -- Cardinal Health today announced that executives of the ... Goldman Sachs CEO Unplugged Conference on ... Conference Center in New York. 28th Annual ... Noon EST at the Westin St. Francis Hotel in ... will discuss Cardinal Health,s diverse products and services, company ...
Breaking Medicine Technology:ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Cardinal Health Executives to Speak at Two Investor Events in January 2New National Nurse Talk Radio Show Takes Off with Humor Health and a Voice for the Patient Advocate 61727 1New National Nurse Talk Radio Show Takes Off with Humor Health and a Voice for the Patient Advocate 61727 2New National Nurse Talk Radio Show Takes Off with Humor Health and a Voice for the Patient Advocate 61727 3Duplicate File Detective v3 0 Provides Enterprise Grade Duplicate File Management 61725 1Duplicate File Detective v3 0 Provides Enterprise Grade Duplicate File Management 61725 2Spray May Delay Ejaculation 61723 1Spray May Delay Ejaculation 61723 2
... WEST CHESTER, Ohio, Jan. 7 AtriCure, Inc.,(Nasdaq: ... a leader in cardiac surgical,ablation products, today announced ... products, which physicians have adopted to,treat atrial fibrillation ... by Dr. James H. Wudel, a prominent cardiac ...
... Fovea Pharmaceuticals SA, which, last,December 2007, raised ... announced that,its product, Recombinant human rod-derived cone ... Medicinal Product from the,European Commission, following the ... Evaluation of Medicinal Products (EMEA) Committee for ...
Other Medicine Technology:Positive Results Published Using AtriCure Minimally Invasive Products 2Positive Results Published Using AtriCure Minimally Invasive Products 3Positive Results Published Using AtriCure Minimally Invasive Products 4Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa 2Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa 3
CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
Selute Picotip Atrial-J steroid eluting passive fixation lead...
Unipolar temporary atrial pacing lead is smaller and thinner than Medtronics standard temporary pacing leads. It is well suited for thin, delicate, atrial tissue....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: